REGN vs SRCE · P/E 14, rev $14.34B vs P/E 12, $1.61B cap
Regeneron Pharmaceuticals Inc (REGN) versus 1st Source Corporation (SRCE) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
1st Source Corporation (SRCE) is a banks - regional company listed on US.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
SRCE does not have a complete income-statement cache yet.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. SRCE currently screens at market cap $1.61B and trailing P/E 11.5.
Not investment advice. Open the REGN and SRCE stock pages for the full models.
Not investment advice.